Activated oncogenes are the genetic drivers of human cancer progression. Oncogenes become activated by structural DNA alterations, which include: Point mutations, small insertions or deletions, copy number variations and gene translocation/fusion.

Cancer drugs are most effective when they target activated oncogenes and matching the right drug to the right target in the right patient is critical for a positive outcome. The future of molecular oncology depends on the ability to diagnose the oncogenes signature in individual cancer patient.

Recent developments in the sequencing technologies and large-scale comprehensive genomics profiling studies continue to identify recurrent mutations in a subset of genes indicating their role in disease progression.

Today, due to the technological advances and scientific breakthroughs cancer treatment is going through a fundamental transition where the conventional treatment using cytotoxic chemicals is being replaced by less toxic and targeted drugs based on the specific genetic alteration.

The future of molecular oncology depends on the ability to accurately establish the oncogenes signature in individual cancer patients. At ITOS Oncology, we use cutting edge Next Generation Sequencing (NGS) technology to identify specific molecular aberrations driving cancer in individual patients.

Data from existing targeted cancer treatments clearly show that the best response is observed when the activated oncogenes is targeted. On the other hand, among the patients with activated oncogenes who respond to a targeted treatment, the level and duration of response is highly variable. This could be explained by the genomic context of an activated oncogenes that is unique to any given patient. Therefore, the ability to detect complex oncogenes signatures in human cancer specimens is vital for better predictions of the efficacy of targeted agents, and to design therapeutic strategies with multiple targeted agents.

Stay tuned for
Personalized cancer gene panels
Cancer predisposition (heritable) gene panels